|
|
Revenues
|
|
|
|
|
|
|
33,266
|
45,804
|
56,197
|
58,054
|
|
|
Cost of products sold
|
|
|
|
|
|
|
7,439
|
15,387
|
17,446
|
17,414
|
|
|
Selling, general and administrative
|
|
|
|
|
|
|
6,942
|
11,299
|
12,349
|
15,260
|
|
|
Research and development
|
|
|
|
|
|
|
6,407
|
6,557
|
7,084
|
6,510
|
|
|
Acquired IPR&D and milestones
|
|
|
|
|
|
|
385
|
1,200
|
962
|
697
|
|
|
Other operating expense, net
|
|
|
|
|
|
|
890
|
|
-432
|
-56
|
|
|
Total operating costs and expenses
|
|
|
|
|
|
|
20,283
|
34,441
|
38,273
|
39,937
|
|
|
Operating earnings
|
|
|
|
|
|
|
12,983
|
11,363
|
17,924
|
18,117
|
|
|
Interest expense, net
|
|
|
|
|
|
|
-1,509
|
-2,280
|
-2,384
|
-2,044
|
|
|
Net foreign exchange loss
|
|
|
|
|
|
|
-42
|
-71
|
-51
|
-148
|
|
|
Other expense, net
|
|
|
|
|
|
|
-3,006
|
-5,614
|
-2,500
|
-2,448
|
|
|
Earnings before income tax expense
|
|
|
|
|
|
|
8,426
|
3,398
|
12,989
|
13,477
|
|
|
Income tax expense (benefit)
|
|
|
|
|
|
|
544
|
-1,224
|
1,440
|
1,632
|
|
|
Net earnings
|
|
|
|
|
|
|
|
4,622
|
11,549
|
11,845
|
|
|
Net earnings attributable to noncontrolling interest
|
|
|
|
|
|
|
|
6
|
7
|
9
|
|
|
Net earnings attributable to AbbVie Inc.
|
|
|
|
|
|
|
7,882
|
4,616
|
11,542
|
11,836
|
|
|
Earnings Per Share, Basic
|
|
|
|
|
|
|
5.3
|
2.73
|
6.48
|
6.65
|
|
|
Earnings Per Share, Diluted
|
|
|
|
|
|
|
5.28
|
2.72
|
6.45
|
6.63
|
|
|
Weighted Average Number of Shares Outstanding, Basic
|
|
|
|
|
|
|
1,481
|
1,667
|
1,770
|
1,771
|
|
|
Weighted Average Number of Shares Outstanding, Diluted
|
|
|
|
|
|
|
1,484
|
1,673
|
1,777
|
1,778
|
